Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.
Hospital group 340B Health said its Sept. 15 report “finds the three major manufacturers of insulin in the U.S. are reaping additional profits” by denying or limiting 340B discounts when hospitals use contract pharmacies. “People with diabetes and the safety-net providers who care for them are bearing the brunt of the actions,” it said.
Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
